Adaptin Bio, Inc. (APTN)
| Market Cap | 56.40M |
| Revenue (ttm) | n/a |
| Net Income | -5.71M |
| EPS | -0.67 |
| Shares Out | 9.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 6.27 |
| Previous Close | 6.27 |
| Day's Range | 6.27 - 6.27 |
| 52-Week Range | 5.60 - 6.27 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About Adaptin Bio
Adaptin Bio, Inc., a biotechnology company, develops drug delivery technologies to deliver drugs and other compounds directly to target destinations within the body in the United States. It provides Brain Bispecific T-cell Engager platform, a bispecific antibody technology to target and treat intracerebral malignancies, such as gliomas. It develops APTN-101, a proprietary epidermal growth factor receptor variant III to eliminate malignant glioma tumors in a range of aggressive preclinical tumor models. It caters to patients with oncology, CNS, ... [Read more]
Financial Performance
Financial StatementsNews
Adaptin Bio Shares (Ticker: APTN) Commence Trading on the OTCQB
CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Adaptin Bio, Inc. (OTCQB: APTN), (“Adaptin” or the “Company”), a biotechnology company developing precision cancer therapeutics enabled by targeted de...
Adaptin Bio Shares to be Quoted on the OTCQB Under Ticker Symbol APTN
CHARLOTTE, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- Adaptin Bio, Inc. (OTCQB: APTN), (“Adaptin” or the “Company”), a biotechnology company developing precision cancer therapeutics enabled by targeted ...